Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

Now Viewing

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss the increasing treatment options for early-stage and locally advanced resectable non–small cell lung cancer (NSCLC), including neoadjuvant, perioperative, and adjuvant therapies. The decision to pursue surgery first or neoadjuvant therapy is made through multidisciplinary tumor boards or clinics, considering anatomical and functional factors as well as patient needs.

In many cases, neoadjuvant chemoimmunotherapy is provided, and resectability is reassessed after treatment, as events during the neoadjuvant phase may impact a patient’s suitability for surgery. If a patient is deemed unresectable upfront for robust reasons, such as the presence of multistation N2 disease, chemoradiation followed by consolidation therapy may be considered for local control.

Patient goals and the ability to tolerate a year of postsurgical therapy are also important considerations when tailoring treatment approaches. The rapid evolution in managing these patients has led to more patients being considered for surgery who may have been previously directed to chemoradiation. Close collaboration among the surgeon, radiation oncologist, and medical oncologist is crucial in making these treatment decisions.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.